Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease | Zendy

John M. Ringman | Zendy; Giovanni Coppola | Zendy; David Elashoff | Zendy; Yaneth RodríguezAgudelo | Zendy; Luis D. Medina | Zendy; Karen H. Gylys | Zendy; Jeffrey L. Cummings | Zendy; Greg M. Cole | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease

Author(s) -

John M. Ringman,

Giovanni Coppola,

David Elashoff,

Yaneth RodríguezAgudelo,

Luis D. Medina,

Karen H. Gylys,

Jeffrey L. Cummings,

Greg M. Cole

Publication year - 2012

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000335729

Subject(s) - psen1 , cerebrospinal fluid , dementia , alzheimer's disease , medicine , degenerative disease , family history , disease , endocrinology , pathology , psychology , oncology , amyloid precursor protein

Biological markers of utility in tracking Alzheimer's disease (AD) during the presymptomatic prodromal phase are important for prevention studies. Changes in cerebrospinal fluid (CSF) levels of 42-amino-acid β-amyloid (Aβ(42)), total tau protein (t-tau) and phosphorylated tau at residue 181 (p-tau(181)) during this state are incompletely characterized.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research